We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 3 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/4/2024 11:19 | PINGGGGGGGGGGGGGGGGG | thanatos abysss | |
25/4/2024 11:13 | Sorry. Wrong thread | institutional investments | |
24/4/2024 18:47 | Kreature PMd you me us | thanatos abysss | |
24/4/2024 18:04 | Sounds like an odd business model? Maybe not listed on AIM? | kreature | |
24/4/2024 13:26 | No.7 have sales I think its part of their business model so they may be serious about the product | vlad the impaler | |
24/4/2024 13:18 | April 2021 RNS Sbtx an Uni of Manchester research agreement. How d’we know time reversal discoveries aren’t being passed to no.7 ? | kreature | |
24/4/2024 12:24 | all aboard the syme oops rocket | thanatos abysss | |
24/4/2024 12:17 | Did Cathy leave so sbtx wouldn't have an unfair advantage ahead of No.7 ? | institutional investments | |
24/4/2024 12:15 | "No7 Beauty Company and Boots today (11th April 2024) announce the renewal of their 20-year, multi-million-pound partnership with the University of Manchester Centre for Dermatology Research for a further five years" Why why not take it to Sederma? Might be able ro knock it out in five weeks for an RNS, and just sell to investors for 5 years | institutional investments | |
24/4/2024 08:27 | anything to do with us, suspect not and another lost opportunity. University of Manchester, Boots And No7 beauty company renew 20-year partnership to supercharge skin science advancements No7 Beauty Company and Boots today (11th April 2024) announce the renewal of their 20-year, multi-million-pound partnership with the University of Manchester Centre for Dermatology Research for a further five years. The partnership has accelerated discoveries in skin science and paved the way for game-changing skincare products that have fuelled the growth and reputation of the British beauty industry globally. The renewed commitment will help Boots and No7 Beauty Company continue to break new ground in helping people care for their skin throughout their life, whether it is maintaining skin health, helping to combat skin ageing or supporting people through significant skin changes such as those resulting from the menopause. It will also further strengthen their market leading cosmetic science innovation pipeline, which has delivered product innovations generating waiting lists of up to 100,000 people, physical queues outside Boots stores and surges in visits to boots.com. The announcement was made at a special event held at the University, which celebrated some of the partnership’s most significant scientific milestones, including the launch of its biggest scientific breakthrough to date; the ground-breaking No7 Future Renew skincare range. The range was launched exactly one year ago this week and was developed following 15 years of research and development between scientists at both organisations, resulting in the discovery of a world-first super peptide blend formulated into a best-selling range and serum that is clinically proven to reverse visible signs of skin damage. This innovation has taken the beauty industry by storm, with the Future Renew serum becoming a global bestseller and the biggest ever beauty launch in the UK. In the UK, there were more than 500,000 transactions in the first four weeks, and a year later, one product is still sold every seven seconds. The collaboration renewal also coincides with both institutions celebrating landmark anniversaries; with Boots marking its 175th anniversary and The University of Manchester reaching its 200 year milestone in 2024. Mark Winter, Managing Director, No7 Beauty Company, said: “We are incredibly proud of our longstanding partnership with the UoM’s Centre for Dermatology Research and excited for the next phase of our collaboration. Scientific innovation is part of our DNA and by working with world-leading partners like the University of Manchester we are committed to using our unrivalled research expertise to be at the forefront of skincare and cosmetic innovation, developing ground-breaking, clinically proven, affordable products that work for everyone.” | theterrier | |
23/4/2024 14:58 | another great day Glorious RR powering ahead | thanatos abysss | |
23/4/2024 14:40 | Another great day | institutional investments | |
22/4/2024 15:08 | no one listens to us vlad just end it i think you already have | thanatos abysss | |
22/4/2024 15:00 | All these dilutions and cash raises - and nothing budgeted to tell the world they exist? They dont seem to have much issue, making gerbil investors aware though do they? Seems like the only market they have interest in, for brand awareness lol | vlad the impaler | |
22/4/2024 15:00 | just end it nike were right | thanatos abysss | |
22/4/2024 14:56 | years of distributors etc paying the way for 'OPTI brand awareness" But if you google it after those years of 'free marketing brand awareness' all you can find is some orangutan telling you to buy shares at 130p | vlad the impaler | |
22/4/2024 14:55 | At least opti came up with a novel suggestion for not willing to waste real cash on marketing.. "Everyone else will do it for them for free" ffs | vlad the impaler | |
22/4/2024 14:52 | exactly what they have kept on asking us vlad just end it | thanatos abysss | |
22/4/2024 14:44 | What is the point in existing then | vlad the impaler | |
22/4/2024 14:40 | They just don't have the budget to do proper marketing! | deeppockets |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions